Figure 5 from Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer

PI3K pathway alterations are associated with differences in clinical outcomes on elacestrant. Patients with PI3K pathway–altered tumors were defined by the presence of an oncogenic PIK3CA, AKT1, and/or PTEN alteration detected within 6 months prior to elacestrant exposure. Clinical outcomes in patients with PI3K pathway–altered disease (in red) were compared with those without a PI3K pathway alteration (in blue) via the TTNT (depicted in A), TTD (depicted in B), and OS (depicted in C). The adjusted HR and corresponding 95% CI are displayed. Vertical hash marks denote a censored patient event CL, confidence limit.